---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-011887"
form_type: "8-K"
ticker: "GKOS"
cik: "0001192448"
company_name: "GLAUKOS Corp"
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T04:53:29.847345+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Glaukos Q2 net sales $72.7M, down 7% YoY; raises FY2022 guidance to $275-280M

## Summary
- Net sales of $72.7M in Q2 2022, down 7% YoY; glaucoma $56.1M, corneal health $16.6M.
- GAAP net loss of $45.5M ($0.96 EPS) vs loss of $17.5M ($0.38) in Q2 2021; includes $10M IPR&D charge for iVeena licensing.
- Non-GAAP net loss of $39.1M ($0.83) vs $10.1M ($0.22) in prior year.
- Raised 2022 net sales guidance to $275-280M from prior $270-275M.
- Ended Q2 with ~$400M cash and short-term investments.

## SEC filing metadata
- accession: 0001558370-22-011887
- form_type: 8-K
- ticker: GKOS
- cik: 0001192448
- company_name: GLAUKOS Corp
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1192448/000155837022011887/0001558370-22-011887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1192448/000155837022011887/gkos-20220803x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-011887
- JSON: https://secwatch.observer/filing/0001558370-22-011887.json
- Plain text: https://secwatch.observer/filing/0001558370-22-011887.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.